Showing 1,041 - 1,060 results of 106,019 for search '(( 10 mg decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.34s Refine Results
  1. 1041
  2. 1042

    Serum concentrations of FGF23 at baseline and at week 40 in patients that achieved a serum phosphate concentration of <4.5 mg/dL and >4.5 mg/dL). by Cristian Rodelo-Haad (5607911)

    Published 2018
    “…Bars represent median and interquartile range. Serum iFGF23 decreased from 581.0 pg/mL (491.2–886.0) to 238.5 pg/mL (116.7–443.5) [median percent change of 63.8% (-75.2–5.40) in patients that achieved the target of phosphate <4.5 mg/dL. …”
  3. 1043

    Table_1_A phased intervention bundle to decrease the mortality of patients with extracorporeal membrane oxygenation in intensive care unit.pdf by Yajun Jing (11711139)

    Published 2022
    “…In multivariable analysis, even after excluding the confounding factors, such as age, APECHII score, pre-ECMO lactate, and incidence of CRRT during ECMO, the intervention bundle still can decrease the mortality independently, which also remained true in the statistical analysis of V-V and V-A ECMO separately. …”
  4. 1044
  5. 1045

    Table_2_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

    Published 2022
    “…We analyzed the national dataset published by Mexican health authorities, as a retrospective cohort, separating cases, hospitalizations, deaths and excess deaths by wave and age group. …”
  6. 1046

    Table_1_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

    Published 2022
    “…We analyzed the national dataset published by Mexican health authorities, as a retrospective cohort, separating cases, hospitalizations, deaths and excess deaths by wave and age group. …”
  7. 1047
  8. 1048
  9. 1049
  10. 1050
  11. 1051
  12. 1052
  13. 1053
  14. 1054
  15. 1055

    Panel (a) compares SO<sub>2</sub> emissions prescribed over the historical period in the CMIP5 simulations (solid grey) with three inventory-based estimates of historical emissions... by Nathan P Gillett (557010)

    Published 2013
    “…SO<sub>2</sub> emissions over the 21st century specified in the RCP 2.6, 4.5 and 8.5 scenarios [<a href="http://iopscience.iop.org/1748-9326/8/3/034008/article#erl467068bib8" target="_blank">8</a>] (solid coloured lines) are compared with those specified in the SRES A1, A2, B1 and B2 scenarios [<a href="http://iopscience.iop.org/1748-9326/8/3/034008/article#erl467068bib9" target="_blank">9</a>] (dashed coloured lines). …”
  16. 1056

    Tetrahydrohyperforin Inhibits the Proteolytic Processing of Amyloid Precursor Protein and Enhances Its Degradation by Atg5-Dependent Autophagy by Viviana A. Cavieres (500139)

    Published 2015
    “…We show herein that IDN5706 decreases the levels of ER degradation enhancer, mannosidase alpha-like 1 (EDEM1), a key chaperone related to endoplasmic-reticulum-associated degradation (ERAD). …”
  17. 1057
  18. 1058
  19. 1059
  20. 1060

    Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial by Seyyed Abbas Zojaji (5208589)

    Published 2022
    “…<div><p>Abstract Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. …”